Work

Positioning of proteasome inhibitors in therapy of solid malignancies

Year: 2017
Type: review
Abstract: Targeting of the protein degradation pathway, in particular, the ubiquitin-proteasome system, has emerged as an attractive novel cancer chemotherapeutic modality. Although proteasome inhibitors have been most successfully applied in the treatment of hematological malignancies, they also received continuing interest for the treatment of solid tumors. In this review, we summarize the current positioning of proteasome inhibitors in the treatment of common solid malignancies (e.g., lung, colon, pancreas, breast, and head and neck cancer), addressing topics of their mechanism(s) of action, predictive factors and molecular mechanisms of resistance.
Language: English
Open Access status: hybrid
Estimated APC paid: $4,390
OpenAlex ID: W2768999031
FWCI: 1.314
Cites: 177
Cited by: 155
Related to: 10